MET and non-small cell lung carcinoma: Overall, ABBV-399 has shown encouraging efficacy in treating relapsed/refractory nonsquamous NSCLC with c-MET overexpression and wild-type EGFR, but further studies will be needed to validate its efficacy in patients with squamous NSCLC and EGFR-mutant NSCLC.